NCT05487469

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Rheumatic heart disease usually accompanied by weakened immune function. And the cardiopulmonary bypass further aggravating the decline of immune function. Therefore, the prevention of Postoperative immune function collapse is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 may be beneficial. This study was designed to test the hypothesis that the administration of thymosin alpha 1 will Improve the immune function and prognosis of patients.

Conditions

• Rheumatic Heart Disease
• Cardiopulmonary Bypass
• Immunotherapy

Interventions

Type	Name	Description
DRUG	Thymosin Alpha1	Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead
OTHER	Blank Control	the Control group did not receive Thymosin alpha 1 or any placebo.

Timeline

• Start date: 2022-07-01
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2022-08-04
• Last updated: 2022-08-04

Locations

1 site across 1 country: China